Leads To Development
About the deal
London, UK, September 30, 2026 – Clarenta, backed by EdgeCap Partners, today announced that Leads To Development (L2D) has joined Clarenta Group following a majority investment, strengthening Clarenta’s ability to support biotech and pharmaceutical sponsors from preclinical drug development strategy through first-in-human clinical trials and beyond.
The partnership adds specialist non-clinical development, manufacturing, and regulatory expertise at the critical early stages of drug development. Together with Clarenta’s existing early development consulting expertise and Early Phase Unit, L2D’s capabilities strengthen the connection between early scientific strategy and first-in-human clinical research.
“Not only ‘Agile’, but also exceptionally knowledgeable, well connected, committed, and always willing to go the extra mile. Their focus was never simply on getting a deal done; they were genuinely invested in supporting us throughout every stage of the process and ensuring that this transaction created a foundation for long-term success. It was a real pleasure to work with the whole Agile Capital Markets team.”
– Jonathan Kearsey, Managing Director and Co-Founder of Leads To Development